ClinicalTrials.gg
RecruitingNCT06237803EMN36Updated Dec 3, 2025

European Myeloma Network (EMN) Sample Project

An observational study in Multiple Myeloma, Smoldering Multiple Myeloma and Plasma Cell Leukemia, sponsored by European Myeloma Network B.V.. Recruiting at 41 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Primary conditionLeukemia, Plasma CellRegistry: Multiple MyelomaReclassifiedWhy we changed it
Registry
Multiple Myeloma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Plasma Cell
Why
  1. The study's listed conditions name Leukemia, Plasma Cell, a narrower term within Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by European Myeloma Network B.V. · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,000
Ages
18 Years and older
Sex
All
01

Study summary

This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples.

This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples

02

Conditions studied

  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Plasma Cell Leukemia
  • Extramedullary Myeloma
  • MGUS

Browse trials for

03

In context

Leukemia, Plasma Cell Reclassified

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Lead sponsor

European Myeloma Network B.V. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Compared within Leukemia, Plasma Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Myeloma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients in hospitals in countries that participate in European Myeloma Network (EMN) trials; these patients may be included in upfront trials or in maintenance or relapse trials later during their disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD)
  • Subjects are ≥ 18 years old.
  • Subjects have provided written in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures.

    1. Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and
    2. subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care).
  • Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events.
  • Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Subjects with MGUS, SMM, MM, PCL

    Subjects with Monoclonal Gammopathy of Undetermined Significance (MGUS), smouldering Multiple Myeloma (SMM), Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) Timepoints and samples to be collected are the following: * bone marrow aspirate, bone marrow biopsy, EMD biopsy, peripheral blood and serum at baseline; * bone marrow aspirate, bone marrow biopsy, peripheral blood and serum pre-maintenance in TE patients or after 1 year of therapy in Non-Transplant-Eligible (NTE) patients; * bone marrow aspirate, bone marrow biopsy, peripheral blood and serum during maintenance therapy and only if performed as SOC; * bone marrow aspirate, bone marrow biopsy, EMD biopsy peripheral blood and serum at 1st and later PD.

    Other: storage of biological samples

Interventions

  • Otherstorage of biological samples

    collect and store biological samples

06

What researchers measure

Primary outcomes

  1. Biobank

    Collect biological samples for research studies related to improving medicine and care to the patient

    Time frame: up to 30 years

07

Study locations

41 of 41 sites recruiting
  • Alfred Hospital
    Melbourne, Australia
    Recruiting
    • Spencer · Principal investigator
  • KUK Linz
    Linz, Austria
    Recruiting
    • Schmitt · Contact
  • Medical University Vienna
    Vienna, Austria
    Recruiting
    • Krauth · Contact
  • Department of Haematology UZ Leuven Gasthuisberg
    Leuven, Belgium
    Recruiting
    • Delforge · Principal investigator
  • Nemocnice Havířov
    Havířov, Czechia
    Recruiting
    • Mikula · Contact
  • Nemocnice Nový Jičín
    Nový Jičín, Czechia
    Recruiting
    • Wrobel · Contact
  • Fakultní nemocnice
    Olomouc, Czechia
    Recruiting
    • Minařík · Contact
  • Slezská nemocnice
    Opava, Czechia
    Recruiting
    • Stejskal · Contact
  • Fakutni nemocnice Ostrava
    Ostrava, Czechia
    Recruiting
    • Hajek · Contact
  • Nemocnice Pelhrimov
    Pelhřimov, Czechia
    Recruiting
    • Kessler · Contact
  • Všeobecná Fakultní nemocnice v Praz
    Prague, Czechia
    Recruiting
    • Pavlicek · Contact
  • Regional General Hospital Alexandra Dept of Clinical Therapeutics
    Athens, Greece
    Recruiting
    • Terpos · Contact
  • Theagenion Cancer Hospital
    Thessaloniki, Greece
    Recruiting
    • Katodrytou · Contact
  • Beaumont Hospital, Dublin, Hematology Department
    Galway, Ireland
    Recruiting
    • Krawczyk · Principal investigator
  • A.O. 'SS. Antonio e Biagio'
    Alessandria, Italy
    Recruiting
    • Monaco · Contact
  • AOU Ospedali Riuniti di Ancona
    Ancona, Italy
    Recruiting
    • Offidani · Contact
  • Bari-A.O.U. Consorziale Policlinico - Medicina Interna
    Bari, Italy
    Recruiting
    • Ria · Principal investigator
  • Policlinico S Orsola Malpighi
    Bologna, Italy
    Recruiting
    • Zamagni · Contact
  • A.O.Spedali Civili di Brescia
    Brescia, Italy
    Recruiting
    • Belotti · Contact
  • A.S.U.R. Regione Marche
    Civitanova Marche, Italy
    Recruiting
    • Mirabile · Principal investigator
  • A.O.U. Careggi
    Florence, Italy
    Recruiting
    • Antonioli · Contact
  • A.O.U. Policlinico S. Martino - Clinica Ematologica
    Genova, Italy
    Recruiting
    • Cea · Principal investigator
  • A.O.U. Policlinico S. Martino - Ematologia
    Genova, Italy
    Recruiting
    • Aquino · Contact
    • Aquino · Principal investigator
  • A.O. 'Cardinale G.Panico'
    Lecce, Italy
    Recruiting
    • Mele · Principal investigator
  • A.O. di Rilievo Nazionale A. Cardarelli
    Naples, Italy
    Recruiting
    • Palmieri · Contact
  • A.O.U. Maggiore della Carità
    Novara, Italy
    Recruiting
    • Casaluci · Contact
  • Policlinico S. Matteo Fondazione IRCCS - Pavia
    Pavia, Italy
    Recruiting
    • Mangiacavalli · Contact
  • A.O. San Camillo-Forlanini
    Roma, Italy
    Recruiting
    • Garzia · Principal investigator
  • Ospedale S. Eugenio
    Roma, Italy
    Recruiting
    • Ferraro · Principal investigator
  • I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Italy
    Recruiting
    • Falcone · Contact
  • A.O. S. Maria
    Terni, Italy
    Recruiting
    • Liberati · Contact
    • Liso · Principal investigator
  • A.O.U. Città della Salute e della Scienza di Torino - PO Molinette
    Torino, Italy
    Recruiting
    • D'Agostino · Contact
  • Azienda Ospedaliera Universitaria di Udine
    Udine, Italy
    Recruiting
    • Francesca Patriarca · Contact
  • ULSS8 Berica Ospedale S.Bortolo
    Vicenza, Italy
    Recruiting
    • Barillà · Principal investigator
  • CHUC
    Coimbra, Portugal
    Recruiting
    • Roque · Principal investigator
  • Fundação Champalimaud
    Lisbon, Portugal
    Recruiting
    • João · Principal investigator
  • Chsj - Hosp. Sao Joao
    Porto, Portugal
    Recruiting
    • Bergantim · Principal investigator
  • IPOP Porto
    Porto, Portugal
    Recruiting
    • Barreto · Principal investigator
  • Clinic of Hematology, University Clinical Center of Serbia
    Belgrade, Serbia
    Recruiting
    • Bila · Contact
  • CHUV
    Lausanne, Switzerland
    Recruiting
    • Auner · Principal investigator
  • HOCH Health Ostschweiz Kantonsspital St.Gallen
    Sankt Gallen, Switzerland
    Recruiting
    • Driessen · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2037, 180 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Feb 1, 2024
StartActual
Dec 21, 2022
Primary completionEst.
Dec 2037
CompletionEst.
Dec 2037
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06237803
Lead sponsor
European Myeloma Network B.V.
Collaborators
Janssen, LP
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Dec 21, 2022
Primary completion
Dec 2037 (estimated)
Completion
Dec 2037 (estimated)
Last update
Dec 3, 2025

Study contacts

Chiara Del Pietro
Contact
chiara.delpietro@emn.org
+31 10702687065

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion